← Back to Search

Virus Therapy

Imvamune for Non-melanoma Skin Cancer (MUSIC-01 Trial)

Phase 1 & 2

Waitlist Available

Led By Ivan V Litvinov, M.D., Ph.D

Research Sponsored by Ivan Litvinov

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 25 days

Awards & highlights

MUSIC-01 Trial Summary

This trial looks at whether the Imvamune smallpox vaccine is safe and effective in treating non-melanoma skin cancers.

Eligible Conditions

Non-melanoma Skin Cancer
Basal Cell Carcinoma
Squamous Cell Carcinoma

MUSIC-01 Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 25 days

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~25 days

This trial's timeline: 3 weeks for screening, Varies for treatment, and 25 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Maximum Tolerated Dose (MTD)

Objective Tumor Response Rate (ORR)

Secondary outcome measures

Number of T cells/concentration of antigen specific antibodies

Viral load in NMSC tumours

MUSIC-01 Trial Design

1Treatment groups

Experimental Treatment

Group I: ImvamuneExperimental Treatment1 Intervention

Imvamune vaccine to be administered intratumorally at one of three doses on Days 0 and 4 of the study

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Ivan LitvinovLead Sponsor

Ivan V Litvinov, M.D., Ph.DPrincipal InvestigatorMcGill University Health Centre/Research Institute of the McGill University Health Centre

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the primary condition that Imvamune helps alleviate?

"Imvamune is an effective treatment against variola major (smallpox), contraindication to first or second generation smallpox vaccines, and hemorrhagic fever, ebola."

Answered by AI

What is the historical data for Imvamune's efficacy?

"There are currently 17 active studies being conducted on Imvamune. Out of these, 0 are in Phase 3. Most of the research is based in Boston, but there are also 76 other locations running clinical trials for this medication."

Answered by AI

Are patients still being recruited for this clinical trial?

"From what is detailed on clinicaltrials.gov, it appears that this particular clinical trial is still looking for patients to enroll. This information was first posted on November 16th 2020 and updated as recently as November 26th 2020."

Answered by AI

How many people are being given the chance to participate in this trial?

"The clinical trial is recruiting patients, as indicated by the information available on clinicaltrials.gov. This particular study was posted on November 16th 2020 and updated 11 days later. So far, 45 people have been enrolled at a single site."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Imvamune Vaccine for the Treatment of Non-melanoma Skin Cancer

Ivan Litvinov 2020. "Imvamune Vaccine for the Treatment of Non-melanoma Skin Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04410874.